非小细胞肺癌EGFR基因突变与临床特征分析  

作　　者：刘安[1] 陈余清[1] 孙哲[1] 王效静[1] 李伟[1] 闵生萍[1] 

机构地区：[1]蚌埠医学院第一附属医院呼吸与危重症医学科,233000

出　　处：《浙江临床医学》2015年第10期1660-1662,共3页Zhejiang Clinical Medical Journal

摘　　要：目的 探讨非小细胞肺癌（NSCLC）中表皮生长因子受体（EGFR）基因突变特点与临床特征的关系.方法 130例NSCLC肿瘤组织,分别提取DNA,采用突变特异性扩增系统（ARMS）扩增检测EGFR基因外显子18、19、20、21的突变情况.结果 130例NSCLC共检出57例EGFR基因突变（43.8％）,其中18、19、20、21单独突变分别为1例（0.8％）、26例（20％）、1例（0.8％）、23例（17.7％）,主要突变类型为19外显子缺失（构成比45.6％）和外显子21 L858R（构成比38.6％）.女性患者突变率高于男性患者（65.9％ vs 31.3％,P＜0.01）.腺癌患者突变率高于鳞癌患者（51.6％ vs 22.9％,P＜0.01）.不吸烟患者突变率高于吸烟患者（55.3％ vs 27.8％,P＜0.01）.未发现EGFR基因突变率与年龄、病变部位、淋巴结转移相关（P＞0.05）.结论 NSCLC患者EGFR因突变以19、21外显子突变为主,突变以女性、腺癌、不吸烟患者较多见.Objective To investigate gene mutations of the epidermal growth factor receptor （ EGFR ） in patients with non -small cell lung cancer （ NSCLC ） in Anhui and analyze the correlation between mutations and clinical features.Methods Specimens of lung cancer tissues were collected from 130 NSCLC patients in our hospital.DNA was extracted.Mutations of EGFR exons 18, 19, 20 and 21 were detected by amplification refractory mutation system （ ARMS ） .Results Mutations were loud in 57 cases of 130 lung cancer samples, with an incidence of 43.8%., among which, mutations located at exon 18, 19, 20 and 21 were reported in 1 case （ 0.8% ） , 26 cases （20%） , 1 case （ 0.8% ） , 23 cases （ 17.7 ） . The mutation of deletion at exon 19 （ 45.6% 26/57 ） and exon 21 L858R （ 38.6% 22/57 ） were the predominant mutations. Mutation in female patients was higher than in male （ 65.9% vs 31.3% P〈0.01 ） . Mutation in adenocareinoma patients was higher than squamous carcinoma patients （ 51.6% vs 22.9% P〈0.01 ） . Mutation in Non - smokers was higher than smokers （ 55.3% vs 27.8% P〈0.01 ） .The mutation rate of EGFR had no correlation with the age, lesion location and lymph node metastasis of patients with NSCLC （ all P〉0.05 ） .Conclusion Exon 19and 21 mutation were predominant in EGFR gene mutation in NSCLC in Anhui.These mutations were more frequently detected in female, adenocarecinoma and non-smoking patients.

关 键 词：非小细胞肺癌 表皮生长因子受体 基因突变 

分 类 号：R978[医药卫生—药品]